Did you know? You can suggest edits to improve this peptide information.
Overview
What is Ara 290?
Ara 290 (Cibinetide) is an engineered 11-amino acid peptide derived from erythropoietin that activates the Innate Repair Receptor (IRR) to provide tissue-protective effects without stimulating red blood cell production. It has completed multiple Phase 2 clinical trials and holds FDA Orphan Drug status for several indications.
Key Benefits
Proven tissue protection, nerve regeneration, anti-inflammatory effects, excellent safety profile in clinical trials
Mechanism of Action
Activates Innate Repair Receptor (IRR) through EPOR/β-common receptor complex, triggering tissue-protective signaling without erythropoietic effects
Research Indications
Peripheral Nerve Regeneration
23% increase in corneal nerve fiber area demonstrated in clinical trials, with sustained improvement in neuropathic pain
Diabetic Neuropathy Treatment
Significant nerve regeneration and metabolic improvements in Type 2 diabetes patients with peripheral neuropathy
Central Nervous System Protection
Crosses blood-brain barrier to provide neuroprotection in stroke and traumatic brain injury models
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
Ara 290 has a short half-life (~20 minutes) but triggers long-lasting cellular effects. Morning administration may optimize circadian alignment with tissue repair processes.
Peptide Interactions
How to Reconstitute
Important
Always use bacteriostatic water (BAC). Sterile technique is essential.
Allow vial to reach room temperature (15-20 minutes)
Clean vial top with alcohol swab
Slowly inject 1 mL sterile water into vial
Gently swirl to dissolve (do not shake vigorously)
Solution may appear slightly cloudy - this is normal
Use immediately or store at 2-8°C for up to 24 hours
Protect from light during storage and use
Rotate injection sites (anterior thigh recommended)
Quality Indicators
Pharmaceutical grade manufacturing
Clinical trial material manufactured under GMP conditions with full quality documentation
Proper peptide sequence verification
Correct 11-amino acid sequence (pGlu-Glu-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser) with N-terminal pyroglutamate
Sterile lyophilized powder
Proper freeze-drying with excipients like sucrose or mannitol for stability and sterility
Light-sensitive formulation
Requires protection from light during storage, reconstitution, and administration
Clinical batch documentation
Certificates of analysis showing purity >95%, endotoxin levels <1 EU/mg, and sterility testing
Cloudy or discolored solution
Reconstituted solution should be clear to slightly cloudy and colorless - discoloration indicates degradation
What to Expect
- Week 1-2: Initial anti-inflammatory effects, potential mild improvement in pain symptoms
- Week 2-4: Progressive nerve regeneration, improved tissue healing markers, enhanced wound healing if applicable
- Week 4-6: Peak therapeutic effects, maximum nerve fiber density improvements, sustained pain relief
- Month 2-6: Long-lasting benefits continue due to "molecular switch" effect, sustained tissue protection
Side Effects & Safety
- Excellent safety profile in clinical trials with no serious drug-related adverse events
- No anti-drug antibodies detected in human studies
- No hematopoietic effects or risk of polycythemia unlike erythropoietin
- Contraindicated with recent anti-TNF therapy (within 6 months) or EPO use (within 2 months)
- Monitor for injection site reactions and rotate injection sites
- Not recommended during pregnancy or in patients with BMI >34 kg/m²
References
Pancreatic Islet Protection Study (2021)
In vitro study of human pancreatic islets showing Ara 290 protection against inflammatory damage, supporting its potential in diabetes treatment and transplantation.
View Study (opens in new tab) →Diabetic Macular Edema Pilot Study (2020)
Open-label pilot study in 9 patients examining Ara 290 effects on diabetic macular edema, showing good safety profile and improved patient-reported outcomes.
View Study (opens in new tab) →Sarcoidosis Neuropathy Phase 2b Trial (2017)
Double-blind, placebo-controlled trial in 64 patients with sarcoidosis-associated small fiber neuropathy. The 4 mg dose showed significant nerve regeneration and pain reduction in moderate-severe cases.
View Study (opens in new tab) →Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by Nootpedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve Nootpedia